Latest news with #LaurenDonovan
Yahoo
3 days ago
- General
- Yahoo
Why hasn't anyone been charged in Seattle clash arrests? What we know
The Brief A violent clash at Cal Anderson Park led to 22 arrests, with allegations of counter-protesters pushing officers off bikes, stealing batons, and throwing rocks. The King County Prosecuting Attorney's Office clarifies that no charges have been filed yet, as the Seattle Police investigation is ongoing and requires thorough review of video evidence. Prosecutors emphasize the independence of their investigation despite the involvement of police officers as alleged victims, ensuring transparency in their decision-making process. SEATTLE - A violent clash between counter-protesters and police at Cal Anderson Park over the weekend resulted in 22 arrests, including allegations that demonstrators pushed officers off bikes, stole batons, and threw rocks. Now, the central question is whether those suspects will face criminal charges. FOX 13 Seattle's Lauren Donovan spoke with Casey McNerthney of the King County Prosecuting Attorney's Office to clarify the legal process now playing out. While supporters of the arrestees claim the state has declined to charge them, McNerthney says the full picture is more complicated. L: "What exactly happened at court today?" C: "So what folks learned in court this afternoon is the investigation with Seattle Police is still ongoing. It's not correct to say that King County prosecutors have declined cases — because prosecutors have not. We don't have cases to make charging decisions on one way or another. It's still in the investigation phase with Seattle Police. Once those are sent to us, a decision can be made." L: "What's the hold up? How much time do Seattle Police get to look over the evidence?" C: "It's a little different with other cases that make the news, like shootings. With those cases, it's a little more clear cut — where at least you think you know who fired the shot. In a situation like this, what prosecutors want to do is get as much video evidence as possible. "When you see the photos from City Hall and also Cal Anderson, you see almost everyone had their phones up, so we know there's a lot of video out there. There's also body-worn cameras, and we want to see that too. "What police have is as much time as they need under the statute of limitations. Cases don't get better with age, but if they need a week or two to get that information, they can have it." L: "Is there a conflict of interest when the alleged victims in this case are officers?" C: "The investigations will be independent. We're different agencies. We work often with Seattle Police, but we'll be transparent with what our decisions are and why and I think there's enough separation there. I'm not sure everyone will believe that but if they look at our process I think that will come through." The Source Information in this story comes from original reporting by FOX 13 Seattle reporter Lauren Donovan. Ex-Seattle police Chief Adrian Diaz files lawsuit, claims wrongful termination Crews battle Second Creek Fire near Leavenworth, WA 2 injured in separate Seattle shootings Teen, child killed in Lacey, WA mobile home fire Crews investigate explosion at Woodinville, WA hardware store College Inn Pub announces closure after 50 years in Seattle Dave's Hot Chicken to open 4 new locations in Seattle area. Here's where To get the best local news, weather and sports in Seattle for free, sign up for the daily FOX Seattle Newsletter. Download the free FOX LOCAL app for mobile in the Apple App Store or Google Play Store for live Seattle news, top stories, weather updates and more local and national news.
AFP
16-05-2025
- Health
- AFP
Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or 'Zombie' Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Natu
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company's broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called 'zombie' cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue. This press release features multimedia. View the full release here: Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience. Dr. Quarta said, 'We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions.'1 About the Study In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics.1 'Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,'1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. 'We appreciate the valuable support and expertise from the Rubedo team during this research.' About Rubedo Life Sciences Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit References 1. Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). 2. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085. View source version on Investor Contact: Rubedo Chief Business Officer Ali Siam alisiam@ 781-974-9559 Media Contact: Peter Collins 908-499-1200 © Business Wire, Inc. Disclaimer : This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Yahoo
15-05-2025
- Health
- Yahoo
Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or "Zombie" Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo's proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 SAN FRANCISCO, May 15, 2025--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company's broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called "zombie" cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue. Dr. Quarta said, "We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions."1 About the Study In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics.1 "Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,"1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. "We appreciate the valuable support and expertise from the Rubedo team during this research." About Rubedo Life Sciences Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit References 1. Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). 2. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085. View source version on Contacts Investor Contact: Rubedo Chief Business Officer Ali Siamalisiam@ 781-974-9559 Media Contact: Peter 908-499-1200
